Voyager Therapeutics (VYGR) Interest & Investment Income (2014 - 2026)

Voyager Therapeutics has disclosed Interest & Investment Income across 13 years of filings, most recently posting $1.9 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $1.9 million, down 41.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (down 44.85% YoY), and the FY2025 annual result was $10.6 million, down 42.07% from the prior year.
• Interest & Investment Income came in at $1.9 million for Q1 2026 at Voyager Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.9 million in Q2 2024 to a low of $31000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $2.8 million (2025), against an average of $2.6 million.
• Across the five-year window, Interest & Investment Income soared 5912.9% in 2023 and slumped 47.91% in 2025, its largest moves.
• Voyager Therapeutics' Interest & Investment Income stood at $976000.0 in 2022, then soared by 223.16% to $3.2 million in 2023, then grew by 26.63% to $4.0 million in 2024, then slumped by 47.15% to $2.1 million in 2025, then slipped by 9.43% to $1.9 million in 2026.
• The last three Interest & Investment Income figures came in at $1.9 million (Q1 2026), $2.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.